Innoviva (INVA) Non-Current Debt (2010 - 2026)
Innoviva (INVA) posted Non-Current Debt of $258.1 million for Q1 2026, little changed on a QoQ basis from $257.7 million in Q4 2025, and up 0.56% year-over-year from $256.7 million in Q1 2025.
Innoviva (INVA) Non-Current Debt (2010 - 2026) Analysis & Trends
Innoviva's Non-Current Debt history runs 14 years deep, the most recent figure standing at $258.1 million for Q1 2026.
- Quarterly Non-Current Debt rose 0.56% year-over-year to $258.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $258.1 million (up 0.56% YoY) and the FY2025 annual result came in at $257.7 million, up 0.55% from the prior year.
- Non-Current Debt was $258.1 million for Q1 2026 at Innoviva, roughly flat from $257.7 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $447.3 million in Q2 2024 and bottomed at $256.0 million in Q3 2024.
- A 5-year average of $357.5 million and a median of $443.7 million in 2022 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt rose 13.1% — and 2024, when it sank 42.57%.
- Innoviva's Non-Current Debt stood at $444.2 million in 2022, then increased by 0.46% to $446.2 million in 2023, then slumped by 42.56% to $256.3 million in 2024, then gained by 0.55% to $257.7 million in 2025, then climbed by 0.14% to $258.1 million in 2026.
- Business Quant data shows INVA's Non-Current Debt at $258.1 million in Q1 2026, $257.7 million in Q4 2025, and $257.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | 258.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 258.10 Mn |
| Dec 31, 2025 | 257.73 Mn |
| Sep 30, 2025 | 257.38 Mn |
| Jun 30, 2025 | 257.02 Mn |
| Mar 31, 2025 | 256.67 Mn |
| Dec 31, 2024 | 256.32 Mn |
| Sep 30, 2024 | 255.97 Mn |
| Jun 30, 2024 | 447.28 Mn |
| Mar 31, 2024 | 446.76 Mn |
| Dec 31, 2023 | 446.23 Mn |
| Sep 30, 2023 | 445.72 Mn |
| Jun 30, 2023 | 445.20 Mn |
| Mar 31, 2023 | 444.69 Mn |
| Dec 31, 2022 | 444.18 Mn |
| Sep 30, 2022 | 443.68 Mn |
| Dec 31, 2021 | 394.65 Mn |
| Sep 30, 2021 | 392.30 Mn |
| Jun 30, 2021 | 389.99 Mn |
| Mar 31, 2021 | 387.73 Mn |
| Dec 31, 2020 | 385.52 Mn |